Home / Private raises / Graviton BioScience Corp
Graviton BioScience Corp
Biotechnology · New York, New York · $5.0M sold across 1 offering
Form D filings (1)
| Filed | Form | Sold | Offered | Investors | Exemption | Securities | First sale | |
|---|---|---|---|---|---|---|---|---|
| 2026-11-16 | D (new) | $5.0M | $75.0M | 2 | 506(b) | Equity | Oct 23 | SEC ↗ |
An update (D/A) restates the running total of its offering, so the total above counts each offering's latest figure once.
Issuer
| Industry | Biotechnology |
| Located | New York, New York |
| Entity | Corporation |
| Incorporated | Delaware |
| SEC CIK | 1847048 |
People named in the latest filing
| Name | Role |
|---|---|
| Samuel D Waksal | Executive Officer, Director, Promoter |
| Rui Wu | Executive Officer |
| David MacMillan | Director |
| Ran Nussbaum | Director |
| James Boylan | Director |
| Dixon Boardman | Director |
| Michael Baran | Director |
Names and roles as filed with the SEC. Addresses are not shown.
Source: SEC EDGAR Form D filings. Amounts are self-reported by the issuer. Not investment advice.
How are we doing?
